Sulfadiazine

Sulfadiazine

SCHEMBL570072

Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1.[Zn]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfadiazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.96
AURKA O14965 1/20 0.96
DHFR P00374 1/20 0.96
TSHR P16473 1/20 0.96
SMN1; SMN2 Q16637 2/20 0.66
CYP2C9 P11712 2/20 0.65
MAPT P10636 2/20 0.65
ALDH1A1 P00352 4/20 0.59
TDP1 Q9NUW8 3/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 1/20 0.57
CYP3A4 P08684 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.56
PRMT1 Q99873 1/20 0.56
KDM4E B2RXH2 2/20 0.55
EDNRA P25101 1/20 0.55
SLC6A4 P31645 1/20 0.55
ADRA1A P35348 1/20 0.55
PRMT6 Q96LA8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfadiazine SCHEMBL18668477 0.98 LMNA (0.93) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL10422849 0.98 LMNA (1.00) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL24176 0.98 LMNA (1.00) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL30080807 0.98 LMNA (1.00) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL34517 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL5870705 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL6141086 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL11611850 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL5870853 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL3728176 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005895-A Biological dressing and preparation method and application thereof 天津市托福医用原子能科技有限公司 2026-05-12 CN claimed
CN-119269423-A Method for determining lead salt in sulfadiazine zinc raw material 河南省药品医疗器械检验院(河南省疫苗批签中心) 2025-01-07 CN claimed
CN-118697691-A Skin injury treatment ointment and preparation method thereof 邵明冰 2024-09-27 CN claimed
CN-114533655-A Improved sulfadiazine zinc-silver cream and preparation method thereof 中国人民武装警察部队特色医学中心 2022-05-27 CN claimed
CN-114103295-A Regenerated environment-friendly antibacterial fabric cloth and preparation method thereof 安徽亿盈特纤新材料有限公司 2022-03-01 CN claimed
CN-113293512-A Antibacterial skin-friendly non-woven fabric and preparation method thereof 冠和卫生用品有限公司 2021-08-24 CN claimed
CN-113279144-A Environment-friendly degradable non-woven fabric and preparation method thereof 冠和卫生用品有限公司 2021-08-20 CN claimed
US-20210094954-A1 PREPARATION METHODS AND APPLICATIONS OF 3,5-DISUBSTITUTED METHYLPYRAZOLO[1,5-A]PYRIMIDINE-7-HYDROXYLIC SALTS XU LIFENG (US) 2021-04-01 US claimed
CN-112007006-A A pharmaceutical composition for treating oral ulcer, and its preparation method 山东省药学科学院 2020-12-01 CN claimed
CN-109224015-A A kind of rheumatic arthritis ointment 湖北科田药业有限公司 2019-01-18 CN claimed
CN-1660442-A Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method UNIV CHINA OCEAN (CN) 2005-08-31 CN claimed
CN-1312078-A Making process of compound sulfadiazine zinc spreader CHENGDU CITY INST OF MEDICINE (CN) 2001-09-12 CN claimed
CN-1299293-A Adhesive applicator with polymerization agent and/or bioactive material CLOSURE MEDICAL CORP (US) 2001-06-13 CN claimed
EP-1073484-A1 ADHESIVE APPLICATOR WITH POLYMERIZATION AGENTS AND/OR BIOACTIVE MATERIAL Closure Medical Corporation (US) 2001-02-07 EP claimed
WO-1999055394-A1 ADHESIVE APPLICATOR WITH POLYMERIZATION AGENTS AND/OR BIOACTIVE MATERIAL CLOSURE MEDICAL CORPORATION (US) 1999-11-04 WO claimed
EP-0480189-A1 Pharmaceutical compositions for topical use comprising hyaluronic acid sodium salt and disinfectant substances ALTERGON S.A. (CH) 1992-04-15 EP claimed
US-4579731-A POLYVINYL ALCOHOL, POLYVINYLPYROLIDONE, AND GLYCEROL KEY PHARMACEUTICALS, INC. (US) 1986-04-01 US claimed
US-4559223-A ANTICARIES AGENTS, ANTIPLAQUE AGENTS, GINGIVAL INHIBITORS DALTEX MEDICAL SCIENCES, INC. (US) 1985-12-17 US claimed
US-4078058-A Cerium sulfadiazine for treating burns RESEARCH CORPORATION (US) 1978-03-07 US claimed
US-4049802-A Zinc sulfadiazine and its use in the treatment of burns RESEARCH CORPORATION (US) 1977-09-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094954-A1 PREPARATION METHODS AND APPLICATIONS OF 3,5-DISUBSTITUTED METHYLPYRAZOLO[1,5-A]PYRIMIDINE-7-HYDROXYLIC SALTS DHPS, NUDT1, DPYD LMNA 4063/4885AURKA 578/4885DHFR 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.